Volume 30, Issue 3 (Summer 2024)
Intern Med Today 2024, 30(3): 127-132 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Farashi Bonab S, Bijari B, Farashi E, Khansari N. Evaluation of Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) Level in Lymphocytes Exposed to Breast Tumor Cell Lysate. Intern Med Today 2024; 30 (3) :127-132
URL: http://imtj.gmu.ac.ir/article-1-4058-en.html
URL: http://imtj.gmu.ac.ir/article-1-4058-en.html
1- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran & Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran , sfarashib@tums.ac.ir
2- Department of Medical Laboratory Sciences, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran
3- Department of Cardiothoracic Surgery, Imam Reza Medical Research & Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
4- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Medical Laboratory Sciences, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran
3- Department of Cardiothoracic Surgery, Imam Reza Medical Research & Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
4- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (72 Views)
Malignant tumors and cancers are leading causes of death in human societies. T lymphocytes are the main cells in antitumor immunity. One of the best-known inhibitory receptors of T lymphocytes is cytotoxic T lymphocyte antigen-4 (CTLA-4), which plays a crucial role in immunological tolerance. This study aimed to examine the CTLA-4 expression on lymphocytes following exposure to breast tumor cell lysate. We used the 4T1 mouse model of triple-negative breast carcinoma in vitro to evaluate the effect of tumor cell lysate on CTLA-4 expression on T lymphocytes. Tumor cell lysate was prepared from cultured 4T1 tumor cells. Leukocytes were isolated from Balb/c mice and cultured in the presence of tumor cell lysate (tumor cell lysate-treated group) or in the absence of tumor cell lysate (control group). After 4 days of incubation, the leukocytes from both groups were stained with fluorophore-conjugated anti-CD3 and anti-CTLA-4 monoclonal antibodies and analyzed by flow cytometry. Analysis of flow cytometry data showed that the frequency of T lymphocytes was not altered in the tumor cell lysate-treated group compared to the control group (P > 0.05). However, the frequency of CTLA-4+ T lymphocytes in the tumor cell lysate-treated group was higher than that in the control group (1.68% vs. 0.97%, P = 0.05). These results indicate that tumor cell antigens or other tumor cell components may increase CTLA-4 expression on T lymphocytes, thereby dampening the antitumor immune responses. The observed upregulation of CTLA-4+ T lymphocytes in the presence of breast tumor cell lysate suggests that targeting this molecule with monoclonal antibodies may enhance the efficacy of anticancer therapy in patients with breast cancer.
Keywords: Antitumor Immune Response, Breast tumor, Cytotoxic T Lymphocyte Antigen-4, Lymphocytes, Tumor cell lysate
Type of Study: Original |
Subject:
Basic Medical Science
Received: 2024/01/23 | Accepted: 2024/03/28 | Published: 2024/05/30
Received: 2024/01/23 | Accepted: 2024/03/28 | Published: 2024/05/30
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |